Surrozen, Inc.

NASDAQ:SRZN

Biotechnology

Healthcare
$31.74 -4.74%

-$1.14 today

Market cap
$237.33M
Beta
0.51
P/E (TTM)
-0.7
EPS (TTM)
-$31.29
52W Low $8.00High $35.00

Volume 0.31M

Average 0.11M

SRZN Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Surrozen, Inc.NASDAQ: SRZN

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin widens to -2550.1%

Net margin was -2550.1% in Q1 FY2026, up 193.5 pp from a year earlier. On a trailing-twelve-month basis it was -4571.1%, down 3869.1 pp year over year. Over 3 fiscal years it narrowed by 6672.7 pp.

Context

  • Net margin widened in 0 of the last 2 fiscal years.
  • FY2025 was the lowest level in the 3 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 4 analysts of -1154.2% for the fiscal year ending Dec 2026, up from -6960.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-2550.1%+32139.1 pp QoQ
Last fiscal yearDec 2025
-6960.8%-6364.2 pp YoY
LTMMar 2026
-4571.1%-3869.1 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+193.5 pp-7288.9 pp-7482.4 pp
1 year-6364.2 pp+5806.6 pp+12170.8 pp
3 years-6672.7 pp+3386.3 pp+10059.0 pp
5 years+5185.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-6960.8%
Year-over-year change
-6364.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How SRZN compares with its peers on the latest reported figures

  • SRZN's LTM Mar 2026 net margin of -4571.1% is the lowest of the 4 companies compared; the peer median is -468.7%.
  • Its year-over-year change of -3869.1 pp is the lowest of 4, against a peer median of +97.4 pp.
  • Over three fiscal years its change of -6672.7 pp compares with a peer median of +176.5 pp.
SRZN Competitors Peer median
Net Margin for SRZN and competitors
Company Period LTM level YoY 3-year change
AGENAgenus Inc.LTM Mar 202652.2% +243.7 pp+224.6 pp
SEERSeer, Inc.LTM Mar 2026-468.7% +97.4 pp+176.5 pp
IRDOpus Genetics, Inc.LTM Mar 2026-892.4% -462.9 pp-394.2 pp
SRZNSurrozen, Inc.LTM Mar 2026-4571.1% -3869.1 pp-6672.7 pp
IMMXImmix Biopharma, Inc.FY2025— ——
GLSIGreenwich LifeSciences, Inc.FY2025— ——
CGTXCognition Therapeutics, Inc.FY2025— ——
TILInstil Bio, Inc.FY2025— ——
Peer median (excluding SRZN) -468.7%+97.4 pp+176.5 pp

Competitors are the stored peer set for SRZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue012.5M010.66M3.48M
Cost of Revenue3.3M3.27M27.23M0537K
Gross Profit(3.3M)9.23M(27.23M)10.66M2.94M
Gross Margin—73.8%—100.0%84.6%
Research & Development36.88M37.01M27.23M21.13M29.37M
Selling, General & Admin14.21M19.83M15.8M15.06M16.2M
Operating Expenses51.09M53.57M18.55M36.19M45.03M
Depreciation & Amortization3.3M1.96M1.91M1.44M537K
EBITDA(51.35M)(34.05M)(41.13M)(62.12M)(241.49M)
EBITDA Margin—-272.4%—-583.0%-6945.3%
Operating Income(54.39M)(44.34M)(45.78M)(25.54M)(42.09M)
Operating Margin—-354.7%—-239.7%-1210.6%
Interest Income72K781K2.34M1.69M3.02M
Interest Expense00000
Other Income / Expenses(257K)8.34M2.74M(38.03M)(199.93M)
Income Before Tax(54.65M)(36M)(43.04M)(63.56M)(242.03M)
Pre-Tax Margin—-288.0%—-596.6%-6960.8%
Income Tax Expense00000
Net Income(52.51M)(36M)(43.04M)(63.56M)(242.03M)
Net Margin—-288.0%—-596.6%-6960.8%
EPS (Basic)(23.40)(15.55)(21.33)(21.67)(32.37)
EPS (Diluted)(23.40)(15.55)(21.33)(21.67)(32.37)
Weighted Avg Shares2.34M2.31M2.02M2.93M7.48M
Weighted Avg Shares (Diluted)2.34M2.31M2.02M2.93M7.48M

Surrozen, Inc.

NASDAQ:SRZN

Intrinsic Alpha fair value

Locked

Current Price

$31.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.